Abnormalities of the serotonergic system in diacylglycerol kinase δ-deficient mouse brain
- Department of Chemistry, Graduate School of Science, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba, 263-8522 (Japan)
Highlights: • DGKδ deficiency increased SERT protein levels in the mouse cerebral cortex. • DGKδ interacted and co-localized with SERT. • DGKδ deficiency decreased TPH-2 expression and increased MAO-A expression. • The amount of 5-HT was significantly decreased in DGKδ-deficient mice. • OCD-like behaviors in DGKδ-KO mice are caused by composite serotonergic hypofunction. We previously reported that brain-specific diacylglycerol kinase (DGK) δ-knockout (KO) mice showed obsessive-compulsive disorder (OCD)-like behaviors, which were alleviated by a serotonin (5-HT) transporter (SERT) inhibitor. However, the molecular mechanisms causing the OCD-like abnormal behaviors remain unclear. In the present study, we found that DGKδ deficiency increased SERT protein levels in the mouse cerebral cortex. Moreover, DGKδ interacted and co-localized with SERT. Furthermore, DGKδ-KO decreased tryptophan hydroxylase-2 expression and increased monoamine oxidase-A expression. Indeed, the amount of 5-HT in the cerebral cortex was significantly decreased in DGKδ-KO mice. These data strongly suggest that OCD-like behaviors in the DGKδ-KO mice are caused by comprehensive and composite serotonergic hypofunction.
- OSTI ID:
- 23137274
- Journal Information:
- Biochemical and Biophysical Research Communications, Vol. 497, Issue 4; Other Information: Copyright (c) 2018 Elsevier Inc. All rights reserved.; Country of input: International Atomic Energy Agency (IAEA); ISSN 0006-291X
- Country of Publication:
- United States
- Language:
- English
Similar Records
Suppression of NLRP3 inflammasome attenuates stress-induced depression-like behavior in NLGN3-deficient mice
3,4-Methylenedioxymethamphetamine and 3,4-methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of (/sup 3/H)paroxetine-labeled serotonin uptake sites